Halozyme Therapeutics, Inc. (HALO) is a biotechnology company specializing in the development and commercialization of unique enzyme-based therapies for a variety of diseases. The company was incorporated in 1998, with its headquarters in San Diego, California. HALO is known for its proprietary enzyme, hyaluronidase, which breaks down hyaluronic acid (HA), a naturally occurring sugar that can inhibit the delivery of injected medications and fluids. The company has optimized this enzyme to enhance the effectiveness and delivery of other drugs.
The company's most prominent product is Enhanze®, a patented drug delivery technology based on this modified hyaluronidase. Enhanze® allows to create subcutaneous administration for drugs that were previously administered intravenously, resulting in a better patient's experience and reduced healthcare costs. Halozyme has partnered with leading pharmaceutical companies, like Roche and Janssen, to license Enhanze® for their blockbuster drugs.
Halozyme’s own pipeline consists of PEGPH20, a first-in-class treatment for pancreatic cancer. PEGPH20 specifically breaks down HA in the tumor microenvironment, thereby enhancing drug delivery to the tumor and consequently improving the efficacy of chemotherapy.
Halozyme's leadership team comprises accomplished experts in the field of biotechnology with years of experience and commitment to the mission of improving patients’ lives. The company follows a patient-centric approach in every aspect of its research, development, and marketing of therapeutics. Accompanied by a culture of innovation and collaboration, Halozyme is committed to making significant contributions to the biotech industry and global health overall.
Internationally recognized for its innovative approach and lifesaving technologies, Halozyme maintains a strong financial position with robust revenue streams and a solid balance sheet. The company's business model is asset-light, which means that it doesn't incur high manufacturing and infrastructure costs, making it able to respond rapidly to changing market conditions.
Despite its remarkable contributions, Halozyme continues to rigorously pursue research in the hope of making further advances in the field of medicine, aiming to constantly improve the standard of care for patients worldwide. As such, investing in Halozyme Therapeutics represents an opportunity to participate in the growing biotechnology industry and contribute to the improvement of healthcare solutions on a global scale.